RT Journal Article
SR Electronic
T1 Risk of serious adverse effects with Janus kinase inhibitors
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP dtb-2022-000078
DO 10.1136/dtb.2022.000078
YR 2023
UL http://dtb.bmj.com/content/early/2023/01/09/dtb.2022.000078.abstract
AB Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.